{"id":459739,"date":"2025-05-22T00:00:00","date_gmt":"2025-05-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0009-2025-biopharma-dry-eye-unmet-need-unmet-need-dry-eye-disease-us-eu\/"},"modified":"2026-03-31T10:26:05","modified_gmt":"2026-03-31T10:26:05","slug":"unneop0009-2025-biopharma-dry-eye-unmet-need-unmet-need-dry-eye-disease-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0009-2025-biopharma-dry-eye-unmet-need-unmet-need-dry-eye-disease-us-eu\/","title":{"rendered":"Dry Eye &#8211; Unmet Need &#8211; Unmet Need &#8211; Dry Eye Disease US\/EU"},"content":{"rendered":"<p>Dry eye disease (<abbr title=\"dry eye disease\">DED<\/abbr>), also known as keratoconjunctivitis sicca, is a chronic, multifactorial, and highly heterogeneous ophthalmic condition that negatively affects patient\u2019s vision and quality of life. The signs and symptoms of <abbr title=\"dry eye disease\">DED<\/abbr> vary widely among patients, making its management challenging. Beyond conservative measures like lid hygiene and over-the-counter artificial tears, the U.S. <abbr title=\"dry eye disease\">DED<\/abbr> therapy market includes <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved therapies such as AbbVie\u2019s Restasis, Bausch + Lomb\u2019s Xiidra, Bausch + Lomb \/ Novaliq\u2019s Miebo, Harlow\u2019s Vevye, and Viatrist\u2019s Tyrvaya. The European market has fewer approved therapies (e.g., cyclosporin anti-inflammatory eyedrops, Santen\u2019s Ikervis, Thea\u2019s Vevizye). Despite these approved options, multiple off-label therapies, including antibiotics and corticosteroids, remain central to managing <abbr title=\"dry eye disease\">DED<\/abbr>. Understanding the factors that influence physicians\u2019 treatment decisions and identifying the greatest areas of unmet need in <abbr title=\"dry eye disease\">DED<\/abbr> treatment will be crucial for the strategic positioning of novel agents in this market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW141914638 BCX0 round-bullets\">\n<li>What are the most important factors driving ophthalmologists\u2019 prescribing decisions for <abbr title=\"dry eye disease\">DED<\/abbr>?<\/li>\n<li>How do <abbr title=\"dry eye disease\">DED<\/abbr> therapies perform on key clinical attributes?<\/li>\n<li>What are the prevailing areas of unmet need in <abbr title=\"dry eye disease\">DED<\/abbr> treatment?<\/li>\n<li>What trade-offs are surveyed ophthalmologists willing to make across key clinical attributes and price for a new therapy for <abbr title=\"dry eye disease\">DED<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Unmet Need<\/em> offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW141914638 BCX0 round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<div>\n<p style=\"\"><strong>Geography:<\/strong>\u00a0United States, France, Germany, United Kingdom<\/p>\n<p style=\"\"><strong>Primary research:\u00a0<\/strong>Survey of 60 U.S. and 30 European ophthalmologists<\/p>\n<\/div>\n<div><strong>Key drugs covered:<\/strong> Restasis, Ikervis, Vevye \/ Vevizye, Xiidra, Miebo, Tyrvaya<\/div>\n","protected":false},"template":"","class_list":["post-459739","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-dry-eye","biopharma-therapy-areas-ophthalmology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/459739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/459739\/revisions"}],"predecessor-version":[{"id":575785,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/459739\/revisions\/575785"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=459739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}